Research indicates that integrin αvβ3 regulates GLUT3 expression through the PAK4-YAP/TAZ axis, thereby controlling the dependence of patient-derived glioma spheres on GLUT3, offering an effective target for combating the most invasive and drug-resistant cancer stem cells (CSCs) (Cosset et al., 2017). Here, SLC2A3 is linked to central nervous system cancer.